Biogen to pay $700M to boost stake in Samsung biologics joint venture
June 28, 2018 at 16:36 PM EDT
The joint venture, called Samsung Bioepis, has gotten a handful of biosimilar drugs approved in Europe, the U.S. and various foreign nations since being founded six years ago.
